These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 11448091)

  • 1. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze.
    Ferris P; Seward E; Dawson GR
    J Psychopharmacol; 2001 Jun; 15(2):76-82. PubMed ID: 11448091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice.
    Linden AM; Shannon H; Baez M; Yu JL; Koester A; Schoepp DD
    Psychopharmacology (Berl); 2005 Apr; 179(1):284-91. PubMed ID: 15619115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam.
    Tizzano JP; Griffey KI; Schoepp DD
    Pharmacol Biochem Behav; 2002 Sep; 73(2):367-74. PubMed ID: 12117591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition.
    Schlumberger C; Schäfer D; Barberi C; Morè L; Nagel J; Pietraszek M; Schmidt WJ; Danysz W
    Behav Pharmacol; 2009 Feb; 20(1):56-66. PubMed ID: 19179851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors.
    Helton DR; Tizzano JP; Monn JA; Schoepp DD; Kallman MJ
    J Pharmacol Exp Ther; 1998 Feb; 284(2):651-60. PubMed ID: 9454811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
    Rorick-Kehn LM; Perkins EJ; Knitowski KM; Hart JC; Johnson BG; Schoepp DD; McKinzie DL
    J Pharmacol Exp Ther; 2006 Feb; 316(2):905-13. PubMed ID: 16223873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABA(A) signaling.
    Klodzinska A; Tatarczyńska E; Chojnacka-Wójcik E; Nowak G; Cosford ND; Pilc A
    Neuropharmacology; 2004 Sep; 47(3):342-50. PubMed ID: 15275823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
    Fell MJ; Perry KW; Falcone JF; Johnson BG; Barth VN; Rash KS; Lucaites VL; Threlkeld PG; Monn JA; McKinzie DL; Marek GJ; Svensson KA; Nelson DL
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1126-36. PubMed ID: 19755662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil.
    Schmidt-Mutter C; Pain L; Sandner G; Gobaille S; Maitre M
    Eur J Pharmacol; 1998 Jan; 342(1):21-7. PubMed ID: 9544788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt.
    Savić MM; Obradović DI; Ugresić ND; Cook JM; Yin W; Bokonjić DR
    Pharmacol Biochem Behav; 2004 Oct; 79(2):279-90. PubMed ID: 15501303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats.
    Koltunowska D; Gibula-Bruzda E; Kotlinska JH
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():242-9. PubMed ID: 23623810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine.
    Schreiber R; Lowe D; Voerste A; De Vry J
    Eur J Pharmacol; 2000 Jan; 388(2):R3-4. PubMed ID: 10666513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.
    Linden AM; Greene SJ; Bergeron M; Schoepp DD
    Neuropsychopharmacology; 2004 Mar; 29(3):502-13. PubMed ID: 14694349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending the Specificity of DRL 72-s Behavior for Screening Antidepressant-Like Effects of Glutamatergic Clinically Validated Anxiolytic or Antidepressant Drugs in Rats.
    Marek GJ; Salek AA
    J Pharmacol Exp Ther; 2020 Jul; 374(1):200-210. PubMed ID: 32265323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze.
    Kõks S; Soosaar A; Võikar V; Bourin M; Vasar E
    Neuropeptides; 1999 Feb; 33(1):63-9. PubMed ID: 10657473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The anxiolytic-like effects of the neurosteroid allopregnanolone: interactions with GABA(A) receptors.
    Brot MD; Akwa Y; Purdy RH; Koob GF; Britton KT
    Eur J Pharmacol; 1997 Apr; 325(1):1-7. PubMed ID: 9151931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavan-3-ol derivatives are positive modulators of GABA(A) receptors with higher efficacy for the alpha(2) subtype and anxiolytic action in mice.
    Fernandez SP; Mewett KN; Hanrahan JR; Chebib M; Johnston GA
    Neuropharmacology; 2008 Oct; 55(5):900-7. PubMed ID: 18657554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transepithelial transport of the group II metabotropic glutamate 2/3 receptor agonist (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and its prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344).
    Varma MV; Eriksson AH; Sawada G; Pak YA; Perkins EJ; Zimmerman CL
    Drug Metab Dispos; 2009 Jan; 37(1):211-20. PubMed ID: 18838508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats.
    Shekhar A; Keim SR
    Neuropharmacology; 2000 Apr; 39(7):1139-46. PubMed ID: 10760357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.